Chun Tang1, Xiaohua Wang1, Yingying Xie1, Xiaoyan Cai2, Na Yu2, Yudan Hu1, Zhihua Zheng3. 1. Department of Nephrology, Kidney and Urology Center, the Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, China. 2. Department of Rheumatology, Guangzhou First People's Hospital, The Second Affiliated Hospital of South China University of Technology, Guangzhou, China. 3. Department of Nephrology, Kidney and Urology Center, the Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, Chinazhzhihua@mail.sysu.edu.cn.
Abstract
BACKGROUND/AIMS: Increased production of multiple pro-inflammatory cytokines, including tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6, plays an essential pathogenic role in the progression of systemic lupus erythematosus (SLE). Recent studies have characterized itaconate as a novel and potent nuclear-factor-E2-related factor 2 (Nrf2) activator that activates Nrf2 signaling by alkylating cysteine residues on Keap1 (Kelch-like ECH-associated protein 1). METHODS: THP-1 human macrophages and peripheral blood mononuclear cells (PBMCs) of SLE patients were treated with 4-octyl itaconate (OI). Nrf2 signaling activation was tested by qPCR assay and western blotting. mRNA expression and the production of multiple pro-inflammatory cytokines were tested by qPCR and enzyme-linked immunosorbent assays, respectively. Nuclear factor (NF)-κB activation was tested by the p65 DNA-binding assay. RESULTS: We demonstrated that OI, the cell-permeable derivative of itaconate, induced Keap1-Nrf2 dissociation, Nrf2 protein accumulation, and nuclear translocation, which enabled the transcription and expression of multiple Nrf2-dependentantioxidant enzymes (heme oxygenase-1, NAD(P)H:quinone oxidoreductase 1, and glutamate-cysteine ligase modifier subunit) in THP-1 human macrophages. OI also induced significant Nrf2 activation in SLE patient-derived PBMCs. OI pretreatment inhibited mRNA expression and the production of multiple pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) in SLE patient-derived PBMCs and lipopolysaccharide (LPS)-activated THP-1 cells. OI potently inhibited NF-κB activation in SLE patient-derived PBMCs and LPS-activated THP-1 cells. Importantly, Nrf2 silencing (by targeted short hairpin RNA) or knockout (by CRISPR/Cas9 gene-editing method) almost abolished OI-induced anti-oxidant and anti-inflammatory actions in SLE patient-derived PBMCs and LPS-activated THP-1 cells. CONCLUSION: OI activates Nrf2 signaling to inhibit the production of pro-inflammatory cytokines in human macrophages and SLE patient-derived PBMCs. OI and itaconate could have important therapeutic value for the treatment of SLE.
BACKGROUND/AIMS: Increased production of multiple pro-inflammatory cytokines, including tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6, plays an essential pathogenic role in the progression of systemic lupus erythematosus (SLE). Recent studies have characterized itaconate as a novel and potent nuclear-factor-E2-related factor 2 (Nrf2) activator that activates Nrf2 signaling by alkylating cysteine residues on Keap1 (Kelch-like ECH-associated protein 1). METHODS: THP-1 human macrophages and peripheral blood mononuclear cells (PBMCs) of SLEpatients were treated with 4-octyl itaconate (OI). Nrf2 signaling activation was tested by qPCR assay and western blotting. mRNA expression and the production of multiple pro-inflammatory cytokines were tested by qPCR and enzyme-linked immunosorbent assays, respectively. Nuclear factor (NF)-κB activation was tested by the p65 DNA-binding assay. RESULTS: We demonstrated that OI, the cell-permeable derivative of itaconate, induced Keap1-Nrf2 dissociation, Nrf2 protein accumulation, and nuclear translocation, which enabled the transcription and expression of multiple Nrf2-dependentantioxidant enzymes (heme oxygenase-1, NAD(P)H:quinone oxidoreductase 1, and glutamate-cysteine ligase modifier subunit) in THP-1 human macrophages. OI also induced significant Nrf2 activation in SLEpatient-derived PBMCs. OI pretreatment inhibited mRNA expression and the production of multiple pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) in SLEpatient-derived PBMCs and lipopolysaccharide (LPS)-activated THP-1 cells. OI potently inhibited NF-κB activation in SLEpatient-derived PBMCs and LPS-activated THP-1 cells. Importantly, Nrf2 silencing (by targeted short hairpin RNA) or knockout (by CRISPR/Cas9 gene-editing method) almost abolished OI-induced anti-oxidant and anti-inflammatory actions in SLEpatient-derived PBMCs and LPS-activated THP-1 cells. CONCLUSION:OI activates Nrf2 signaling to inhibit the production of pro-inflammatory cytokines in human macrophages and SLEpatient-derived PBMCs. OI and itaconate could have important therapeutic value for the treatment of SLE.
Authors: Aaqib Sohail; Azeem A Iqbal; Nishika Sahini; Fangfang Chen; Mohamed Tantawy; Syed F H Waqas; Moritz Winterhoff; Thomas Ebensen; Kristin Schultz; Robert Geffers; Klaus Schughart; Matthias Preusse; Mahmoud Shehata; Heike Bähre; Marina C Pils; Carlos A Guzman; Ahmed Mostafa; Stephan Pleschka; Christine Falk; Alessandro Michelucci; Frank Pessler Journal: PLoS Pathog Date: 2022-01-13 Impact factor: 6.823
Authors: Edward R Sherwood; Katherine R Burelbach; Margaret A McBride; Cody L Stothers; Allison M Owen; Antonio Hernandez; Naeem K Patil; David L Williams; Julia K Bohannon Journal: J Immunol Date: 2022-02-15 Impact factor: 5.422